Telix Pharmaceuticals average price target trimmed to $17.95
Across 12 analysts, Telix's average 12-month price target slipped from $18.12 to $17.95, while the consensus rating stays at Buy.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
According to TradingView, citing FactSet data, the average 12-month price target for Telix Pharmaceuticals fell from $18.12 to $17.95 based on estimates from 12 analysts. Individual forecasts range from $13.18 to $22.08 per share.
Based on the October 20 closing price, the updated target implies roughly 61% potential upside. The consensus rating remains Buy: of the 14 analysts covering the stock, 13 rate it Buy, one Hold and none Sell.
why it matters
The slight reduction in the average target suggests analysts have become marginally more cautious, though overall sentiment on the stock remains positive. Revisions of this size usually reflect small model adjustments and rarely move the broader market on their own.
tags
instruments
sources
- Telix Pharmaceuticals Limited Stock 12‑Month Price Target Cut to $17.95, Implies 61% Upside — TradingView, 21 October 2026 at 19:20 UTC
- Boeing Company (The) Stock 12‑Month Price Target Cut to $262.43, Implies 38% Upside — TradingView, 21 October 2026 at 22:20 UTC
- Hesai Group Stock 12‑Month Price Target Cut to $27.5, Implies 97% Upside — TradingView, 21 October 2026 at 22:20 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗